| |
FAS (45 patients)
|
|---|
|
Dose Group
|
Chloroprocaine 1%
|
|
Group 30 mg
|
Group 40 mg
|
Group 50 mg
|
|
Gender
|
|
Female n (%)
|
6
|
6
|
6
|
|
Male n (%)
|
9
|
9
|
9
|
|
Age (years)
|
|
Mean ± SD
|
40.8 ± 12.1
|
39.4 ± 12.5
|
41.5 ± 13.9
|
|
Median (range)
|
42 (22–58)
|
41 (19–58)
|
40 (10–63)
|
|
Body weight (kg)
|
|
Mean ± SD
|
73.27 ± 14.11
|
70.27 ± 13.32
|
74.07 ± 13.14
|
|
Median (range)
|
78 (47–99)
|
66 (52–99)
|
73 (48–98)
|
|
Height (cm)
|
|
Mean ± SD
|
172 ± 6.9
|
170.2 ± 9.3
|
168.9 ± 7.1
|
|
Median (range)
|
170 (158–185)
|
173 (153–185)
|
170 (153–180)
|
|
BMI (kg/m2)
|
|
Mean ± SD
|
24.65 ± 3.96
|
24.19 ± 3.62
|
25.87 ± 3.71
|
|
Median (range)
|
25.3 (18.8–30.6)
|
22.2 (19.0–30.6)
|
25.8 (18.3–31.3)
|
|
Race
|
|
Mestizo n (%)
|
1 (6.7%)
|
1 (6.7%)
|
0
|
|
White n (%)
|
14 (93.3%)
|
14 (93.3%)
|
15 (100%)
|
